secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0000950170-24-003387
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity expects Q4 biomaterial/biobanking net sales up 176–193% YoY, full year up 23–27%
--------------------------------------------------------------------------------

- Q4 2023 net sales expected $11.4M–$12.1M, up 176–193% vs Q4 2022.
- Full year 2023 net sales expected $22.06M–$22.76M, up 23–27% vs FY 2022.
- Excludes other revenue, including the Regeneron research collaboration agreement.
- Company plans to provide 2024 revenue guidance soon; aims to boost cash flow from commercial products.
- Actual Q4 and FY 2023 net sales and total revenue to be announced later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/celu-20240103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer